COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS
申请人:Alios Bio Pharma, Inc.
公开号:US20150238498A1
公开(公告)日:2015-08-27
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
Compounds for the treatment of paramyxovirus viral infections
申请人:JANSSEN BIOPHARMA, INC.
公开号:US11014935B2
公开(公告)日:2021-05-25
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein
作者:Baohe Tian、Meizi He、Shixing Tang、Indira Hewlett、Zhiwu Tan、Jiebo Li、Yinxue Jin、Ming Yang
DOI:10.1016/j.bmcl.2009.02.116
日期:2009.4
HIV-1 capsid protein (CA) plays important roles in the viral replication cycle. A number of acylhydrazone derivatives that act as inhibitors of HIV-1 CA assembly, were designed and synthesized. The synthesized compounds were tested for their antiviral activities and cytotoxicities using CEM cells. Some derivatives also were assayed for their ability to inhibit HIV-1 CA assembly in vitro. Among them, compounds 14f and 14i display the most promising potency with EC50 values of 0.21 and 0.17 mu M, respectively. (C) 2009 Elsevier Ltd. All rights reserved.
COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS
申请人:Alios BioPharma, Inc.
公开号:US20170283429A1
公开(公告)日:2017-10-05
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).